Completely
Natural! The WSN® Nerve Support Formula is a medical food specifically Reduce
the symptoms of your neuropathy, safely and effectively |
Benfotiamine Slowing the Process of Cellular Aging Benfotiamine
Inhibits Intracellular Formation of Third Medical Department, We have demonstrated previously that intracellular formation of the advanced glycation end product (AGE) N-epsilon-(carboxymethyl)-lysine (CML) inversely correlates with diabetic vascular complications independently from glycemia (Diabetologia 42, 603, 1999).Here, we studied the effect of benfotiamine, a lipid-soluble thiamine derivative with known AGE-inhibiting properties in-vitro on the intracellular formation of (CML) and methylglyoxal-derived AGE in red blood cells. Blood was collected from 6 Type 1 diabetic patients(2 m, 4 f, age 31.8 ± 5.5 years; diabetes duration 15.3 ± 7.0 years) before and after treatment with 600 mg/day benfotiamine for 28 days. In addition to HbA1c (HULK), CML and methylglyoxal were measured using specific antibodies and a quantitative dot blot technique While treatment with benfotiamine did not affect HbA1c levels (at entry: 7.18±0.86%; at conclusion 6.88±0.88%; p not significant), levels of CML decreased by 40 % (737 ± 51 arbitray unit/mg protein (AU) vs. 470 ± 86 AU; p<0.001). The levels of intracellular methylglyoxal-derived AGE were reduced by almost 70% (1628 ±1136 AU vs. 500 ± 343 AU; p < 0.01). The data indicate that thiamine derivatives are effective inhibitors of both intracellular glycoxidation and AGE formation. INTRODUCTION Intracellular formation of the advanced
glycation end product (AGE) Ne-(carboxymethyl)lysine (CML) inversely correlates
with diabetic vascular complications independently from glycemia. (1)
Intracellular CML is generated by the oxidation of Amadori products or,
alternatively, by lipid peroxidation (2,3). The dicarbonylmethylglyoxal
is formed by non-oxidative fragmentation of glycolysis-derived triosephosphates
and is the most important intracellular AGE (4,5). Study group: six patients
(2 males, 4 females), age31.8 ± 5.5 years; diabetes duration 15.3 ± 7.0
years. Treatment with 600 mg/day benfotiamine for 28days after informed
consent and approval by the local ethics committee. Venous EDTA-blood
(3 ml) drawn before and at the end of the study, samples lysed and
centrifuged, adjusted to identical hemoglobin concentrations. Quantitative
immunoblotting carried out essentially as described before (1). Statistical
analysis was performed using the alternate Welsh t test. Thiamine derivatives, in particular the lipid-soluble pro-drug benfotiamine, are effective inhibitor of intracellular formation of AGE and CML. References:
©
2005-2008 Wellness Support Network, Inc. All Rights Reserved.
WSN®
is a registered trademark of Wellness Support Network, Inc.
Reproduction of this website in full or in part is prohibited without the express written permission of Wellness Support Network, Inc.
|